• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study offers tips for managing patients on antithrombotic drugs


Research finds many physicians unaware of guidelines for surgery cases

It can be important to stratify the ophthalmic surgeries depending on the risk of development of hemorrhagic complications during the perioperative period.

Patients who undergo ophthalmic surgery are often concomitantly taking antithrombotic drugs, i.e., antiplatelets and anticoagulants, during the perioperative period may require different management than patients not taking those drugs. Investigators at St. Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, UK, surveyed ophthalmologists regarding this scenario and reported that most physicians were comfortable with managing patients taking antiplatelets. However, the survey indicated that the situation was not so clear-cut when patients were taking warfarin and direct oral anticoagulants (DOACs).

Achini K. Makuloluwa, MD, NHS Greater Glasgow and Clyde, and his research team reported that there was variability in managing patients on warfarin and DOACs.1 A startling finding was that “40% (of ophthalmologists) were unaware of existing guidelines” for managing these patients, according to the survey. The researchers also found that within the aging population, more patients are taking these drugs to prevent and treat cardiovascular and ischemic cerebral disease.

“Continuing antithrombotic agents perioperatively may increase the risk of potentially sight-threatening haemorrhagic complications, whereas discontinuing these medications may increase the risk of life-threatening thromboembolic events,” the researchers noted. “Therefore, it is important to understand the indications of antithrombotic agents and when it may be safe to discontinue them peri-operatively.”

Researchers also pointed out that it was important to stratify the ophthalmic surgeries depending on the risk of development of hemorrhagic complications during the perioperative period. Based on these concerns, they conducted a PubMed search from January 2007 to August 2017 to identify articles that provided recommendations on managing antithrombic agents during the perioperative period of ophthalmic surgeries and reviewed the incidence rates of the associated hemorrhagic complications. The research team also reviewed all guidelines in the UK from the Royal College of Ophthalmologists and British Society of Haematology.Study findings

The literature recommendations noted that all antithrombotic agents be continued for routine cataract surgeries that were performed under topical or sub-Tenon’s anesthesia. For sharp-needle anesthesia, the literature recommended that surgeons avoid dual antiplatelet therapy and patients could continue taking warfarin if the International Normalized Ratio (INR) was within the therapeutic range. For glaucoma surgery, the literature recommended that aspirin and clopidogrel be discontinued when the drugs are monotherapy for primary prevention, but they can be continued for secondary prevention of cardiovascular diseases.

P2Y12 receptor inhibitors should be discontinued if used as dual antiplatelet therapy. However, the risks and benefits of continuation of antiplatelet agents need special consideration in neovascular glaucoma and high intraocular pressure.

“It is also important to consider and recognize that, intraoperative and postoperative hemorrhagic complications in glaucoma, especially if sustained or prolonged, can cause severe visual loss due to high pressure in already compromised optic nerves,” the researchers explained.

“Anticoagulants should be discontinued with consideration for bridging therapy depending on patient’s risk factors.” For vitreoretinal surgery, the literature results were considered controversial. “The recommendations for perioperative management are similar to that for glaucoma surgery,” the study noted.

“Antithrombotic agents are to be discontinued where possible and to be cautious of these agents in the presence of neovascular retinal diseases.”

For oculoplastic and lacrimal surgery, procedures that are carried out posterior to the orbital septum and deep orbital surgery are associated with potentially sight-threatening hemorrhagic complications, and lacrimal surgery also is considered a high-risk procedure. Procedures that are performed anterior to the orbital septum are considered low risk.

“Expert groups on oculoplastic surgery recommend stopping antithrombotic agents during blepharoplasty, lacrimal surgery and deep orbital surgery as these are considered high risk for sight-threatening hemorrhagic complications,” according to the researchers.

For strabismus surgery, the recommendations are similar to those for glaucoma and vitreoretinal surgeries. For corneal surgery, no evidence was found. Hemorrhagic complications were reported in all groups.Study recommendations

The authors proposed their pathway for managing patients taking antithrombotic drugs. For low-risk procedures (sub-Tenon/topical cataract, corneal, chalazion, eyelid cyst/lesion removal, and strabismus surgeries), antiplatelets can be continued. For anticoagulants, the INR should be check on the surgical day and warfarin continued if within the therapeutic range; the DOAC dose is stopped two days preoperatively (depending on renal function) and restarted one to two days postoperatively, if adequate hemostasis is achieved.

For high-risk procedures (peri/retrobulbar anesthesia, glaucoma, vitreoretinal (pars plana vitrectomy), vitreoretinal procedures [oncology: endoresection, biopsy of intraocular tumors, plaques/markers], oculoplastics [blepharoplasty, postseptal eyelid surgery], and temporal artery biopsy surgeries], antiplatelets are stopped seven days preoperatively but continued in high-risk patients.

Prasugrel, a platelet-aggregation inhibitor [Effent in the US; Efent in the European Union] is stopped seven days preoperatively, and Ticagrelor, [a platelet-aggregation inhibitor] five days preoperatively.

For the anticoagulants (warfarin), the local anticoagulant service should be informed at the time of listing. If low risk (e.g., non-valvular atrial fibrillation), warfarin should be stopped two days preoperatively, the INR is checked on the surgical day, and continued if < 2.

Physicians should discuss potential issues with high-risk patients. For the DOACs, the recommended action is the same as for low-risk procedures. The authors emphasized the importance of considering the indications for antithrombotic agents and the risk of thromboembolic events and hemorrhagic complications depending on the patient and surgery. Bridging anticoagulation should be considered when oral anticoagulants are discontinued.

“The most appropriate surgical procedure should be offered to the patient depending on the risk of haemorrhage perioperatively when anti-thrombotic agents are continued,” the authors concluded. “When urgent surgery is required or when a patient’s case is complex, it is important to take a multidisciplinary approach to the perioperative management of anti-thrombotic agents.”


1. A.K. Makuloluwa, S, Tiew, M. Briggs, Peri-operative management of ophthalmic patients on antithrombotic agents: a literature review, Eye 2019; 1044-1059

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.